3.37MMarket Cap
LossP/E TTM
Jupiter Neurosciences Inc
Key Figures
0.089Open
0.096High
23.06MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
63.55%Turnover Ratio
0.098Prev. Close
0.083Low
1.46MTurnover
LossP/E Static
-1.21P/B
0.00%Div Yield TTM
-205.98%ROA
3.33052wk High
7.47Volume Ratio
-2.44MNet Profit
36.28MShares
-0.2620EPS TTM
--Beta
-6529.17%ROE
0.17252wk Low
12.82%Amplitude
76.61%Gross Margin
3.37MMarket Cap
-7.50Reward/Risk
7.51%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Jupiter Neurosciences Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 200 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Jupiter Neurosciences Inc's Score
Support & Resistance

Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Jupiter Neurosciences Inc Highlights
StrengthsRisks
Jupiter Neurosciences Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Jupiter Neurosciences Inc
JUNS
1
Ionis Pharmaceuticals Inc
IONS
25
Indicators
Financial Indicators
EPS

Relevant data have not been disclosed by the company yet.
Total revenue

Relevant data have not been disclosed by the company yet.
Jupiter Neurosciences Inc Info
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Ticker SymbolJUNS
CompanyJupiter Neurosciences Inc
CEORosen (Christer)
Websitehttps://jupiterneurosciences.com/
Shareholders
FAQs
What is the current price of Jupiter Neurosciences Inc (JUNS)?
The current price of Jupiter Neurosciences Inc (JUNS) is 0.09.
What is the symbol of Jupiter Neurosciences Inc?
The ticker symbol of Jupiter Neurosciences Inc is JUNS.
What is the 52-week high of Jupiter Neurosciences Inc?
The 52-week high of Jupiter Neurosciences Inc is 3.33.
What is the 52-week low of Jupiter Neurosciences Inc?
The 52-week low of Jupiter Neurosciences Inc is 0.17.
What is the market capitalization of Jupiter Neurosciences Inc?
The market capitalization of Jupiter Neurosciences Inc is 3.37M.
Is Jupiter Neurosciences Inc (JUNS) currently rated as Buy, Hold, or Sell?
According to analysts, Jupiter Neurosciences Inc (JUNS) has an overall rating of Buy, with a price target of 25.00.
What is the Earnings Per Share (EPS TTM) of Jupiter Neurosciences Inc (JUNS)?
The Earnings Per Share (EPS TTM) of Jupiter Neurosciences Inc (JUNS) is -0.25.